An unusual manifestation of clear cell carcinoma – case report
More details
Hide details
Department of Gynaecology and Obstetrics, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
Agnieszka Marta Witkowska   

Department of Gynaecology and Obstetrics, University Clinical Center to them. prof. K. Gibińskiego Medical University of Silesia, Katowice, Poland, ul. Medyków 14, 40-752 Katowice, Poland
Ann. Acad. Med. Siles. 2018;72:257–260
The metabolism of neoplastic cells is perceived as the cause of atherothrombotic incidents in cancers since the 19th century. Those incidents occur in 1–11% cancer cases. In clear cell carcinoma, accounting for 5% of ovarian cancers, atherothrombotic incidents tend to occur 2.5 times more frequently. Clear cell carcinoma is diagnosed earlier and at a younger age compared to other ovarian cancers. The cancer is also characterized by drug resistance to standard treatment. A 47-year-old patient was admitted to the Department of Gynaecology and Obstetrics of School of Medicine in Katowice to treat a tumor of the right ovary. The tumor was detected a month before during the diagnostics of an ischemic stroke which occurred despite no risk factors being present. A laparotomy was performed and the tumor, left adnexa and uterus were removed, according to ovarian cancer protocol. Histopathological examination confirmed the diagnosis of adenocarcinoma clarocellulare (clear cell carcinoma – CCC). The patient was referred for further oncological treatment on 5th day after surgery. Oncological alertness needs to be maintained in cases of unexplained atherothrombotic incidents. An interdisciplinary approach can improve patients’ prognosis by diagnosing the cancer earlier.
Matsuura Y., Robertson G., Marsden D.E., Kim S.N., Gebski V., Hacker N.F. Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol. Oncol. 2007; 104(2): 406–410.
Kaur S., Kerkar R.A., Maheshwari A., Shylasree T.S., Gupta S., Deodhar K. Clinical characteristics with patterns of relapse and survival analysis of ovarian clear cell carcinoma. Indian J. Cancer 2016; 53(2): 288–291, doi: 10.4103/0019-509X.197719.
Mizuno M., Kikkawa F., Shibata K., Kajiyama H., Ino K., Kawai M., Nagasaka T., Nomura S. Long-Term Follow-Up and Prognostic Factor Analysis in Clear Cell Adenocarcinoma of the Ovary. J. Surg. Oncol. 2006; 94(2): 138–143.
Chan J.K, Teoh D., Hu J.M., Shin J.Y., Osann K., Kapp D.S. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol. Oncol. 2008; 109(3): 370–376, doi: 10.1016/j.ygyno.2008.02.006.
Kim S.J., Kimoto Y., Nakamura H., Taguchi T., Tanji Y., Izukura M., Shiba E., Takai S. Ovarian Carcinoma with Fistula Formation to the Sigmoid Colon and Ileum: Report of a Case. Surg. Today 1999; 29(5): 449–452.
Duska L.R., Garrett L., Henretta M., Ferriss J.S., Lee L., Horowitz N. When ‘never-events’ occur despite adherence to clinical guidelines: The case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. Gynecol. Oncol. 2010; 116(3): 374–377, doi: 10.1016/j.ygyno.2009.10.069.
Kuan A.S., Teng C.J., Wu H.H., Su V.Y., Chen Y.T., Chien S.H., Yeh C.M., Hu L.Y., Chen T.J., Tzeng C.H., Liu C.J. Risk of ischemic stroke in patients with ovarian cancer: a nationwide population-based study. BMC Med. 2014; 12: 53, doi: 10.1186/1741-7015-12-53.
Dearborn J.L., Urrutia V.C., Zeiler S.R. Stroke and Cancer- A Complicated Relationship. J. Neurol. Transl. Neurosci. 2014; 2(1): 1039.
Kim S.G., Hong J.M., Kim H.Y., Lee J., Chung P.W., Park K.Y., Kim G.M., Lee K.H., Chung C.S., Bang O.Y. Ischemic Stroke in Cancer Patients With and Without Conventional Mechanisms: A Multicenter Study in Korea. Stroke 2010; 41(4): 798–801, doi: 10.1161/STROKEAHA.109.571356.
Schwarzbach C.J., Schaefer A., Ebert A., Held V., Bolognese M., Kablau M., Hennerici M.G., Fatar M. Stroke and Cancer: The Importance of Cancer-Associated Hypercoagulation as a Possible Stroke Etiology. Stroke 2012; 43(11): 3029–3034, doi: 10.1161/STROKEAHA.112.658625.
O'Brien M.E., Schofield J.B., Tan S., Fryatt I., Fisher C., Wiltshaw E. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol. Oncol. 1993; 49(2): 250–254.
Goff B.A., Sainz de la Cuesta R., Muntz H.G., Fleischhacker D., Ek M., Rice L.W., Nikrui N., Tamimi H.K., Cain J.M., Greer B.E., Fuller A.F. Jr. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol. Oncol. 1996; 60(3): 412–417.